^
Association details:
| Biomarker: | KIF5B-RET fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | everolimus (mTOR inhibitor) + Caprelsa (vandetanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged Non-Small Cell Lung Cancer with brain metastases
Excerpt:
Comprehensive genomic profiling revealed fusion of KIF5B (the-kinesin-family-5B-gene) and RET, in addition to AKT2 gene amplification…The addition of everolimus may have both overcome the AKT2 amplification to produce a response in addition to its direct effects on the RET gene. Our case report forms the first evidence of blood-brain-barrier penetration by vandetanib in combination with everolimus.
DOI:
10.1016/j.lungcan.2015.04.004
Trial ID:
